Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases
Purpose Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recom...
Saved in:
| Published in | Breast cancer research and treatment Vol. 180; no. 3; pp. 777 - 790 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.04.2020
Springer Springer Nature B.V Springer Verlag |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0167-6806 1573-7217 1573-7217 |
| DOI | 10.1007/s10549-020-05549-x |
Cover
| Abstract | Purpose
Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.
Methods
We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.
Results
Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.
Conclusion
Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. |
|---|---|
| AbstractList | Purpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.Methods: We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.Results: Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.Conclusion: Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. PurposeDespite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.MethodsWe conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.ResultsAmong 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.ConclusionOur results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.PURPOSEDespite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories.We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.METHODSWe conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories.Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.RESULTSAmong 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped.Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals.CONCLUSIONOur results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories. We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories. Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped. Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. Purpose Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories. Methods We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories. Results Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped. Conclusion Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is sub-optimal for a high proportion of women. However, little is known about long-term patterns of AET adherence over the minimally recommended 5 years. Our objectives were to: (1) identify 5-year AET adherence trajectory groups; (2) describe trajectory groups according to adherence measures traditionally used (i.e., Proportion of Days Covered); and (3) explore factors associated with trajectories. We conducted a 5-year cohort study using data from a French national study that included AET dispensing data. Women diagnosed with first non-metastatic breast cancer and having at least 1 AET dispensing in the 12 months after diagnosis were included. Group-based trajectory modeling was used to identify adherence trajectory groups by clustering similar patterns of monthly AET dispensing. Multinomial logistic regressions were used to identify factors associated with trajectories. Among 674 women, five AET adherence trajectory groups were identified: (1) quick decline and stop (5.2% of women); (2) moderate decline and stop (6.4%); (3) slow decline (17.2%); (4) high adherence (30.0%); and (5) maintenance of very high adherence (41.2%). Mean 5-year Proportion of Days Covered varied from 10 to 97% according to trajectories. Women who did not receive chemotherapy or a personalized care plan were more likely to belong to trajectories where AET adherence declined and stopped. Our results provide information on the diversity of longitudinal AET adherence patterns, the timing of decline and discontinuation and associated factors that could inform healthcare professionals. |
| Audience | Academic |
| Author | Bérenger, Cyril Bouhnik, Anne-Déborah Lauzier, Sophie Bendiane, Marc-Karim Huiart, Laetitia Mondor, Myrto Lambert-Côté, Laurence |
| Author_xml | – sequence: 1 givenname: Laurence surname: Lambert-Côté fullname: Lambert-Côté, Laurence organization: Population Health and Optimal Health Practices Axis, CHU de Quebec – Université Laval Research Centre, Faculty of Pharmacy, Université Laval – sequence: 2 givenname: Anne-Déborah surname: Bouhnik fullname: Bouhnik, Anne-Déborah organization: Aix-Marseille Univ., INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Site Santé Timone, Faculté de Médecine – sequence: 3 givenname: Marc-Karim surname: Bendiane fullname: Bendiane, Marc-Karim organization: Aix-Marseille Univ., INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Site Santé Timone, Faculté de Médecine – sequence: 4 givenname: Cyril surname: Bérenger fullname: Bérenger, Cyril organization: Aix-Marseille Univ., INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, Site Santé Timone, Faculté de Médecine, ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d’Azur, Faculté de Médecine – sequence: 5 givenname: Myrto surname: Mondor fullname: Mondor, Myrto organization: Population Health and Optimal Health Practices Axis, CHU de Quebec – Université Laval Research Centre – sequence: 6 givenname: Laetitia surname: Huiart fullname: Huiart, Laetitia organization: Department of Population Health, Luxembourg Institute of Health – sequence: 7 givenname: Sophie orcidid: 0000-0002-7746-9208 surname: Lauzier fullname: Lauzier, Sophie email: sophie.lauzier@pha.ulaval.ca organization: Population Health and Optimal Health Practices Axis, CHU de Quebec – Université Laval Research Centre, Faculty of Pharmacy, Université Laval, Équipe de Recherche Michel-Sarrazin en Oncologie Psychosociale et Soins Palliatifs (ERMOS), Centre des maladies du sein, CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Cancer Research Centre, Université Laval |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32086655$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-03203214$$DView record in HAL |
| BookMark | eNp9ks9u1DAQxiNURP_AC3BAlpAQB1LGySZOuK0qoEiVuMA5mnXGXa8Su9hO230zHo9Jt7S0QlUOGTm_b2b85TvM9px3lGWvJRxLAPUxSqgWbQ4F5FDN1fWz7EBWqsxVIdVedgCyVnndQL2fHca4AYBWQfsi2y8LaOq6qg6y38t-TYGcJpECbkgnHyxF4Y3AfjNdokuCXO91sI4RZvFiK6ybS2HsJYktYYgCTaIgbIr8zSaLyXoncPTuXFz5kZy4smkt-AL5SAljYkCLVSAuhUYeHz4JFNqvfUgipqnfiilaVmM_csfIy6V5Wo8JVxgpvsyeGxwivbp9H2U_v3z-cXKan33_-u1keZbrSkLKq5WpwajSFHXVt6ZQrVJFq_QCoO9JIi5AgjLs56omaWCxWhChJFJY6raU5VH2Ydd3jUN3EeyIYdt5tN3p8qyzLlIYO2A_y0IuLmf8_Q6_CP7XRDF1o42ahgEd-Sl2RVkXoGQNBaNvH6EbPwXHl2GqKRul2gbuqXMciAcaz1bouWm3rGXTtAXUDVPH_6H46Wm0mmNjLJ8_ELz7R7AmHNI6-mGa_1t8CL653XJajdTfWfA3QgwUO0AHH2Mgc4dI6OacdrucdpzT7ian3TWLmkcibdNNaHhvOzwtLXfSyHPcOYV7255Q_QF-bv3w |
| CitedBy_id | crossref_primary_10_1016_j_breast_2022_01_012 crossref_primary_10_18553_jmcp_2020_26_9_1138 crossref_primary_10_1038_s41523_022_00414_0 crossref_primary_10_1007_s10549_024_07554_w crossref_primary_10_4048_jbc_2023_26_e22 crossref_primary_10_1200_JCO_23_02643 crossref_primary_10_1007_s10549_022_06561_z crossref_primary_10_1007_s10549_020_05748_6 crossref_primary_10_1001_jamanetworkopen_2022_15720 crossref_primary_10_1111_ecc_13749 crossref_primary_10_1097_MLR_0000000000001625 crossref_primary_10_1016_j_breast_2020_11_008 crossref_primary_10_1186_s13058_024_01819_4 crossref_primary_10_3390_curroncol30040288 crossref_primary_10_1016_j_clbc_2021_01_007 crossref_primary_10_2147_PPA_S467892 crossref_primary_10_1186_s12874_023_02019_y crossref_primary_10_1186_s13643_022_01971_y crossref_primary_10_1002_pon_6203 crossref_primary_10_1007_s10549_020_05939_1 crossref_primary_10_1007_s11764_024_01599_y crossref_primary_10_1007_s00432_022_04376_5 crossref_primary_10_1007_s10549_023_06992_2 crossref_primary_10_1093_jamiaopen_ooae006 |
| Cites_doi | 10.1016/S0140-6736(11)60993-8 10.1007/s10549-012-2114-5 10.1002/pds.3787 10.1186/2193-1801-3-282 10.1007/s10549-013-2422-4 10.4159/9780674041318 10.1016/j.drugalcdep.2015.07.363 10.1016/j.ophtha.2015.06.039 10.1177/0049124113503141 10.1159/000360229 10.1200/jco.18.01160 10.1200/JCO.2013.51.7367 10.1002/pds.4647 10.1002/pds.4012 10.1007/s11764-014-0374-2 10.1002/pds.4233 10.1371/journal.pone.0161381 10.1097/MLR.0b013e3182984c1f 10.1002/9781118949740.ch34 10.1016/j.pec.2015.05.013 10.5414/CP202172 10.1214/aos/1176344136 10.1177/0962280215598665 10.1002/pds.4146 10.2147/ppa.S145784 10.1590/S0034-8910.2014048004799 10.1186/1471-2407-14-397 10.1001/jama.2011.506 10.1038/bjc.2012.389 10.1002/9781118949740.ch36 10.1038/bjc.2013.464 10.1016/j.ehrm.2012.10.001 10.1177/1078155212455939 10.1200/JCO.2008.19.2419 10.1007/s10549-010-1132-4 10.1097/01.mlr.0000257193.10760.7f 10.1093/annonc/mdr330 10.1016/j.kjms.2015.04.002 10.1111/tbj.12328 10.1038/bjc.2013.116 10.1007/s10549-017-4561-5 10.1146/annurev.clinpsy.121208.131413 10.1002/cpt.865 10.1200/jco.2009.25.9655 10.1002/pds.4751 10.1136/bmjopen-2014-005971 10.1200/jco.2013.54.2258 10.2147/ppa.s126651 10.1111/j.1365-2125.2012.04167.x 10.1038/sj.bjc.6604758 10.1177/0049124101029003005 |
| ContentType | Journal Article |
| Copyright | Springer Science+Business Media, LLC, part of Springer Nature 2020 COPYRIGHT 2020 Springer Breast Cancer Research and Treatment is a copyright of Springer, (2020). All Rights Reserved. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Springer Science+Business Media, LLC, part of Springer Nature 2020 – notice: COPYRIGHT 2020 Springer – notice: Breast Cancer Research and Treatment is a copyright of Springer, (2020). All Rights Reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 1XC VOOES |
| DOI | 10.1007/s10549-020-05549-x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Consumer Health Database ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1573-7217 |
| EndPage | 790 |
| ExternalDocumentID | oai_HAL_inserm_03203214v1 A618892068 32086655 10_1007_s10549_020_05549_x |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Institut National du Cancer (France) grantid: 05-2011; 05-2011 – fundername: Fonds de recherche du Québec-Santé – fundername: Université Laval funderid: http://dx.doi.org/10.13039/100007867 – fundername: Institut National du Cancer (France) grantid: 05-2011 |
| GroupedDBID | --- -53 -5E -5G -BR -EM -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7W Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM AEIIB PMFND 7TO 7XB 8FK ABRTQ H94 K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO Q9U 7X8 1XC VOOES |
| ID | FETCH-LOGICAL-c510t-5bf60f73f265d9f27977297c400dde1aa40107f100b6e1f04b4eea1ee7a3c9313 |
| IEDL.DBID | 7X7 |
| ISSN | 0167-6806 1573-7217 |
| IngestDate | Fri Sep 12 12:40:57 EDT 2025 Fri Sep 05 07:49:45 EDT 2025 Sat Aug 23 14:02:53 EDT 2025 Tue Jun 17 21:08:05 EDT 2025 Tue Jun 10 20:33:10 EDT 2025 Thu May 22 21:21:11 EDT 2025 Wed Feb 19 02:30:02 EST 2025 Thu Apr 24 22:59:55 EDT 2025 Tue Jul 01 03:38:02 EDT 2025 Fri Feb 21 02:31:53 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Medication adherence Breast cancer Group-based trajectory modeling Adjuvant endocrine therapy |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-5bf60f73f265d9f27977297c400dde1aa40107f100b6e1f04b4eea1ee7a3c9313 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-7746-9208 |
| OpenAccessLink | https://inserm.hal.science/inserm-03203214 |
| PMID | 32086655 |
| PQID | 2383877980 |
| PQPubID | 36266 |
| PageCount | 14 |
| ParticipantIDs | hal_primary_oai_HAL_inserm_03203214v1 proquest_miscellaneous_2362071602 proquest_journals_2383877980 gale_infotracmisc_A618892068 gale_infotracacademiconefile_A618892068 gale_healthsolutions_A618892068 pubmed_primary_32086655 crossref_primary_10_1007_s10549_020_05549_x crossref_citationtrail_10_1007_s10549_020_05549_x springer_journals_10_1007_s10549_020_05549_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200400 2020-04-00 2020-Apr 20200401 2020-04 |
| PublicationDateYYYYMMDD | 2020-04-01 |
| PublicationDate_xml | – month: 4 year: 2020 text: 20200400 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: Netherlands – name: Dordrecht |
| PublicationTitle | Breast cancer research and treatment |
| PublicationTitleAbbrev | Breast Cancer Res Treat |
| PublicationTitleAlternate | Breast Cancer Res Treat |
| PublicationYear | 2020 |
| Publisher | Springer US Springer Springer Nature B.V Springer Verlag |
| Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V – name: Springer Verlag |
| References | Schwarz (CR30) 1978; 6 Lo-Ciganic, Gellad, Gordon, Cochran, Donohue (CR33) 2015; 156 Cortaredona, Pambrun, Verdoux, Verger (CR29) 2017; 26 Lo-Ciganic, Donohue, Kim, Krans, Jones, Kelley, James, Jarlenski (CR34) 2019; 28 (CR3) 2011; 378 Brito, Portela, de Vasconcellos (CR49) 2014; 14 Cluze, Rey, Huiart, BenDiane, Bouhnik, Berenger, Carrieri, Giorgi (CR53) 2012; 23 Cahir, Guinan, Dombrowski, Sharp, Bennett (CR28) 2015; 98 Dillon, Stewart, Smith, Gallagher, Cousins (CR36) 2018; 103 Kimmick, Anderson, Camacho, Bhosle, Hwang, Balkrishnan (CR48) 2009; 27 Nagin (CR16) 2014; 65 Jones, Nagin (CR39) 2013; 42 Danilak, Chambers (CR43) 2013; 19 McCowan, Shearer, Donnan, Dewar, Crilly, Thompson, Fahey (CR12) 2008; 99 Franklin, Shrank, Pakes, Sanfélix-Gimeno, Matlin, Brennan, Choudhry (CR17) 2013; 51 Nagin (CR14) 2005 Grégoire, Moisan, Elseviers, Wettermark, Almarsdóttir, Andersen, Benko, Bennie, Eriksson, Godman, Krska, Poluzzi, Taxis, Vlahović-Palčevski, Stichele (CR7) 2016 Bouhnik, Bendiane, Cortaredona, Sagaon Teyssier, Rey, Berenger, Seror, Peretti-Watel (CR22) 2015 Huiart, Ferdynus, Giorgi (CR4) 2013; 138 Winn, Dusetzina (CR20) 2016; 25 Klijn, Weijenberg, Lemmens, van den Brandt, Lima Passos, Balakrishnan (CR38) 2017; 26 Bezin, Duong, Lassalle, Droz, Pariente, Blin, Moore (CR25) 2017; 26 Modi, Rausch, Glauser (CR37) 2011; 305 McCowan, Wang, Thompson, Makubate, Petrie (CR9) 2013; 109 Nagin, Odgers (CR15) 2010; 6 Sheppard, Faul, Luta, Clapp, Yung, Wang, Kimmick, Isaacs, Tallarico, Barry, Pitcher, Hudis, Winer, Cohen, Muss, Hurria, Mandelblatt (CR42) 2014; 32 Murphy, Bartholomew, Carpentier (CR5) 2012; 134 Trabulsi, Riedel, Winslade, Gregoire, Meterissian, Abrahamovicz, Tamblyn, Mayo, Meguerditchian (CR47) 2014; 20 (CR21) 2014 Makubate, Donnan, Dewar, Thompson, McCowan (CR11) 2013; 108 Van Liew, Christensen, de Moor (CR26) 2014; 8 Hershman, Shao, Kushi, Buono, Tsai, Fehrenbacher, Kwan, Gomez, Neugut (CR10) 2011; 126 Lambert, Balneaves, Howard, Gotay (CR27) 2018; 167 Moon, Moss-Morris, Hunter, Carlisle, Hughes (CR13) 2017; 11 Librero, Sanfelix-Gimeno, Peiro (CR32) 2016; 11 Brito, Portela, de Vasconcellos (CR50) 2014; 48 CR55 Schmidt, Kostev, Jockwig, Kyvernitakis, Albert, Hadji (CR51) 2014; 52 Tervonen, Daniels, Tang, Preen, Pearson (CR19) 2019 Hershman, Kushi, Shao, Buono, Kershenbaum, Tsai, Fehrenbacher, Gomez, Miles, Neugut (CR40) 2010; 28 Newman-Casey, Blachley, Lee, Heisler, Farris, Stein (CR35) 2015; 122 Burstein, Lacchetti, Anderson, Buchholz, Davidson, Gelmon, Giordano, Hudis, Solky, Stearns, Winer, Griggs (CR1) 2019; 37 Brett, Boulton, Fenlon, Hulbert-Williams, Walter, Donnelly, Lavery, Morgan, Morris, Watson (CR52) 2018; 12 Hsieh, Chen, Cheung, Yang (CR46) 2015; 31 Burstein, Temin, Anderson, Buchholz, Davidson, Gelmon, Giordano, Hudis, Rowden, Solky, Stearns, Winer, Griggs (CR2) 2014; 32 Vrijens, De Geest, Hughes, Przemyslaw, Demonceau, Ruppar, Dobbels, Fargher, Morrison, Lewek, Matyjaszczyk, Mshelia, Clyne, Aronson, Urquhart (CR6) 2012; 73 Vrijens, Elseviers, Wettermark, Almarsdóttir, Andersen, Benko, Bennie, Eriksson, Godman, Krska, Poluzzi, Taxis, Vlahović-Palčevski, Stichele (CR8) 2016 Franklin, Krumme, Tong, Shrank, Matlin, Brennan, Choudhry (CR18) 2015; 24 Kemp, Preen, Saunders, Boyle, Bulsara, Malacova, Roughead (CR41) 2014; 3 Kahn, Schneider, Malin (CR54) 2007 CR24 CR23 Jones, Nagin, Roeder (CR31) 2001; 29 Wu, Stafkey-Mailey, Bennett (CR45) 2012; 3 Font, Espinas, Gil-Gil (CR44) 2012 J Bezin (5549_CR25) 2017; 26 AC Modi (5549_CR37) 2011; 305 5549_CR55 C McCowan (5549_CR12) 2008; 99 C Cahir (5549_CR28) 2015; 98 CC Murphy (5549_CR5) 2012; 134 C Cluze (5549_CR53) 2012; 23 J Wu (5549_CR45) 2012; 3 Early Breast Cancer Trialists’ Collaborative Group (5549_CR3) 2011; 378 J Brett (5549_CR52) 2018; 12 VB Sheppard (5549_CR42) 2014; 32 J Van Liew (5549_CR26) 2014; 8 LK Lambert (5549_CR27) 2018; 167 C Brito (5549_CR50) 2014; 48 B Vrijens (5549_CR8) 2016 DL Hershman (5549_CR40) 2010; 28 P Dillon (5549_CR36) 2018; 103 R Font (5549_CR44) 2012 BL Jones (5549_CR31) 2001; 29 DS Nagin (5549_CR15) 2010; 6 N Trabulsi (5549_CR47) 2014; 20 B Makubate (5549_CR11) 2013; 108 J-P Grégoire (5549_CR7) 2016 KL Kahn (5549_CR54) 2007 W-H Lo-Ciganic (5549_CR33) 2015; 156 SL Klijn (5549_CR38) 2017; 26 DS Nagin (5549_CR16) 2014; 65 HE Tervonen (5549_CR19) 2019 C Brito (5549_CR49) 2014; 14 K-P Hsieh (5549_CR46) 2015; 31 J Librero (5549_CR32) 2016; 11 MJ Franklin (5549_CR17) 2013; 51 G Schwarz (5549_CR30) 1978; 6 B Vrijens (5549_CR6) 2012; 73 DL Hershman (5549_CR10) 2011; 126 L Huiart (5549_CR4) 2013; 138 AN Winn (5549_CR20) 2016; 25 S Cortaredona (5549_CR29) 2017; 26 Z Moon (5549_CR13) 2017; 11 HJ Burstein (5549_CR2) 2014; 32 C McCowan (5549_CR9) 2013; 109 D Nagin (5549_CR14) 2005 5549_CR24 5549_CR23 A Kemp (5549_CR41) 2014; 3 JM Franklin (5549_CR18) 2015; 24 G Kimmick (5549_CR48) 2009; 27 A-D Bouhnik (5549_CR22) 2015 Institut national du cancer (5549_CR21) 2014 HJ Burstein (5549_CR1) 2019; 37 PA Newman-Casey (5549_CR35) 2015; 122 N Schmidt (5549_CR51) 2014; 52 WH Lo-Ciganic (5549_CR34) 2019; 28 BL Jones (5549_CR39) 2013; 42 M Danilak (5549_CR43) 2013; 19 |
| References_xml | – volume: 378 start-page: 771 issue: 9793 year: 2011 end-page: 784 ident: CR3 article-title: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(11)60993-8 – volume: 134 start-page: 459 issue: 2 year: 2012 end-page: 478 ident: CR5 article-title: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-2114-5 – volume: 24 start-page: 1105 issue: 10 year: 2015 end-page: 1113 ident: CR18 article-title: Association between trajectories of statin adherence and subsequent cardiovascular events publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.3787 – volume: 3 start-page: 1 issue: 1 year: 2014 end-page: 10 ident: CR41 article-title: Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? publication-title: SpringerPlus doi: 10.1186/2193-1801-3-282 – volume: 138 start-page: 325 issue: 1 year: 2013 end-page: 328 ident: CR4 article-title: A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2422-4 – year: 2005 ident: CR14 publication-title: Group-based modeling of development doi: 10.4159/9780674041318 – volume: 156 start-page: e132 year: 2015 end-page: e132 ident: CR33 article-title: Associations between buprenorphine treatment trajectories and clinical outcomes in a large medicaid program publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2015.07.363 – volume: 122 start-page: 2010 issue: 10 year: 2015 end-page: 2021 ident: CR35 article-title: Patterns of glaucoma medication adherence over four years of follow-up publication-title: Ophthalmology doi: 10.1016/j.ophtha.2015.06.039 – volume: 42 start-page: 608 issue: 4 year: 2013 end-page: 613 ident: CR39 article-title: A note on a stata plugin for estimating group-based trajectory models publication-title: Sociol Methods Res doi: 10.1177/0049124113503141 – volume: 65 start-page: 205 issue: 2–3 year: 2014 end-page: 210 ident: CR16 article-title: Group-based trajectory modeling: an overview publication-title: Ann Nutr Metab doi: 10.1159/000360229 – volume: 37 start-page: 423 issue: 5 year: 2019 end-page: 438 ident: CR1 article-title: Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update publication-title: J Clin Oncol doi: 10.1200/jco.18.01160 – volume: 32 start-page: 2318 issue: 22 year: 2014 ident: CR42 article-title: Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.7367 – volume: 28 start-page: 80 issue: 1 year: 2019 end-page: 89 ident: CR34 article-title: Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4647 – volume: 25 start-page: 953 issue: 8 year: 2016 end-page: 959 ident: CR20 article-title: The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4012 – volume: 8 start-page: 521 issue: 3 year: 2014 end-page: 531 ident: CR26 article-title: Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research publication-title: J Cancer Surviv doi: 10.1007/s11764-014-0374-2 – volume: 26 start-page: 954 issue: 8 year: 2017 end-page: 962 ident: CR25 article-title: The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4233 – volume: 11 start-page: e0161381 issue: 8 year: 2016 ident: CR32 article-title: Medication adherence patterns after hospitalization for coronary heart disease. A population-based study using electronic records and group-based trajectory models (Research Article) (Report) publication-title: PLoS ONE doi: 10.1371/journal.pone.0161381 – volume: 51 start-page: 789 issue: 9 year: 2013 end-page: 796 ident: CR17 article-title: Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence publication-title: Med Care doi: 10.1097/MLR.0b013e3182984c1f – start-page: 355 year: 2016 end-page: 360 ident: CR8 article-title: An introduction to adherence research publication-title: Drug utilization research doi: 10.1002/9781118949740.ch34 – volume: 98 start-page: 1524 issue: 12 year: 2015 end-page: 1539 ident: CR28 article-title: Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: a systematic review and meta-analysis publication-title: Patient Educ Couns doi: 10.1016/j.pec.2015.05.013 – volume: 52 start-page: 933 issue: 11 year: 2014 end-page: 939 ident: CR51 article-title: Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202172 – volume: 6 start-page: 461 issue: 2 year: 1978 end-page: 464 ident: CR30 article-title: Estimating the dimension of a model publication-title: Ann Stat doi: 10.1214/aos/1176344136 – volume: 26 start-page: 2424 issue: 5 year: 2017 end-page: 2436 ident: CR38 article-title: Introducing the fit-criteria assessment plot—a visualisation tool to assist class enumeration in group-based trajectory modelling publication-title: Stat Methods Med Res doi: 10.1177/0962280215598665 – volume: 26 start-page: 402 issue: 4 year: 2017 end-page: 411 ident: CR29 article-title: Comparison of pharmacy-based and diagnosis-based comorbidity measures from medical administrative data publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4146 – volume: 12 start-page: 291 year: 2018 end-page: 300 ident: CR52 article-title: Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S145784 – volume: 48 start-page: 284 issue: 2 year: 2014 end-page: 295 ident: CR50 article-title: Factors associated to persistence with hormonal therapy in women with breast cancer publication-title: Rev Saude Publica doi: 10.1590/S0034-8910.2014048004799 – volume: 14 start-page: 397 year: 2014 ident: CR49 article-title: Adherence to hormone therapy among women with breast cancer publication-title: BMC Cancer doi: 10.1186/1471-2407-14-397 – volume: 305 start-page: 1669 issue: 16 year: 2011 end-page: 1676 ident: CR37 article-title: Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy publication-title: JAMA doi: 10.1001/jama.2011.506 – year: 2012 ident: CR44 article-title: Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in catalonia, spain publication-title: Br J Cancer doi: 10.1038/bjc.2012.389 – start-page: 369 year: 2016 end-page: 380 ident: CR7 article-title: Assessment of adherence to drug treatment in database research publication-title: Drug utilization research doi: 10.1002/9781118949740.ch36 – volume: 109 start-page: 1172 issue: 5 year: 2013 end-page: 1180 ident: CR9 article-title: The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study publication-title: Br J Cancer doi: 10.1038/bjc.2013.464 – year: 2014 ident: CR21 publication-title: La vie deux ans après un diagnostic de cancer – volume: 3 start-page: e195 issue: 4 year: 2012 end-page: e203 ident: CR45 article-title: Long-term adherence to hormone therapy in medicaid-enrolled women with breast cancer publication-title: Health Outcomes doi: 10.1016/j.ehrm.2012.10.001 – volume: 19 start-page: 105 issue: 2 year: 2013 end-page: 110 ident: CR43 article-title: Adherence to adjuvant endocrine therapy in women with breast cancer publication-title: J Oncol Pharm Pract doi: 10.1177/1078155212455939 – volume: 27 start-page: 3445 issue: 21 year: 2009 end-page: 3451 ident: CR48 article-title: Adjuvant hormonal therapy use among insured, low-income women with breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.2419 – volume: 126 start-page: 529 issue: 2 year: 2011 end-page: 537 ident: CR10 article-title: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1132-4 – year: 2007 ident: CR54 article-title: Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use publication-title: Med Care doi: 10.1097/01.mlr.0000257193.10760.7f – volume: 23 start-page: 882 issue: 4 year: 2012 end-page: 890 ident: CR53 article-title: Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time publication-title: Ann Oncol doi: 10.1093/annonc/mdr330 – volume: 31 start-page: 328 issue: 6 year: 2015 end-page: 334 ident: CR46 article-title: Risks of nonadherence to hormone therapy in Asian women with breast cancer publication-title: Kaohsiung J Med Sci doi: 10.1016/j.kjms.2015.04.002 – ident: CR23 – volume: 20 start-page: 632 issue: 6 year: 2014 end-page: 638 ident: CR47 article-title: Adherence to anti-estrogen therapy in seniors with breast cancer: how well are we doing? publication-title: Breast J doi: 10.1111/tbj.12328 – volume: 108 start-page: 1515 issue: 7 year: 2013 end-page: 1524 ident: CR11 article-title: Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality publication-title: Br J Cancer doi: 10.1038/bjc.2013.116 – volume: 167 start-page: 615 issue: 3 year: 2018 end-page: 633 ident: CR27 article-title: Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4561-5 – volume: 6 start-page: 109 year: 2010 end-page: 138 ident: CR15 article-title: Group-based trajectory modeling in clinical research publication-title: Annu Rev Clin Psychol doi: 10.1146/annurev.clinpsy.121208.131413 – volume: 103 start-page: 1052 issue: 6 year: 2018 end-page: 1060 ident: CR36 article-title: Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.865 – volume: 28 start-page: 4120 issue: 27 year: 2010 end-page: 4128 ident: CR40 article-title: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients publication-title: J Clin Oncol doi: 10.1200/jco.2009.25.9655 – year: 2019 ident: CR19 article-title: Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4751 – ident: CR55 – year: 2015 ident: CR22 article-title: The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey) publication-title: BMJ Open doi: 10.1136/bmjopen-2014-005971 – volume: 32 start-page: 2255 issue: 21 year: 2014 end-page: 2269 ident: CR2 article-title: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update publication-title: J Clin Oncol doi: 10.1200/jco.2013.54.2258 – volume: 11 start-page: 305 year: 2017 end-page: 322 ident: CR13 article-title: Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review publication-title: Patient Prefer Adherence doi: 10.2147/ppa.s126651 – volume: 73 start-page: 691 issue: 5 year: 2012 end-page: 705 ident: CR6 article-title: A new taxonomy for describing and defining adherence to medications publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04167.x – ident: CR24 – volume: 99 start-page: 1763 issue: 11 year: 2008 ident: CR12 article-title: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer publication-title: Br J Clin Pharmacol doi: 10.1038/sj.bjc.6604758 – volume: 29 start-page: 374 issue: 3 year: 2001 end-page: 393 ident: CR31 article-title: A SAS procedure based on mixture models for estimating developmental trajectories publication-title: Sociol Methods Res doi: 10.1177/0049124101029003005 – volume: 126 start-page: 529 issue: 2 year: 2011 ident: 5549_CR10 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1132-4 – volume: 32 start-page: 2255 issue: 21 year: 2014 ident: 5549_CR2 publication-title: J Clin Oncol doi: 10.1200/jco.2013.54.2258 – start-page: 369 volume-title: Drug utilization research year: 2016 ident: 5549_CR7 doi: 10.1002/9781118949740.ch36 – volume: 25 start-page: 953 issue: 8 year: 2016 ident: 5549_CR20 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4012 – volume: 6 start-page: 461 issue: 2 year: 1978 ident: 5549_CR30 publication-title: Ann Stat doi: 10.1214/aos/1176344136 – ident: 5549_CR23 – volume: 167 start-page: 615 issue: 3 year: 2018 ident: 5549_CR27 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4561-5 – year: 2012 ident: 5549_CR44 publication-title: Br J Cancer doi: 10.1038/bjc.2012.389 – volume: 11 start-page: e0161381 issue: 8 year: 2016 ident: 5549_CR32 publication-title: PLoS ONE doi: 10.1371/journal.pone.0161381 – volume: 12 start-page: 291 year: 2018 ident: 5549_CR52 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.S145784 – volume: 378 start-page: 771 issue: 9793 year: 2011 ident: 5549_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(11)60993-8 – year: 2015 ident: 5549_CR22 publication-title: BMJ Open doi: 10.1136/bmjopen-2014-005971 – volume: 26 start-page: 402 issue: 4 year: 2017 ident: 5549_CR29 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4146 – volume: 11 start-page: 305 year: 2017 ident: 5549_CR13 publication-title: Patient Prefer Adherence doi: 10.2147/ppa.s126651 – volume: 65 start-page: 205 issue: 2–3 year: 2014 ident: 5549_CR16 publication-title: Ann Nutr Metab doi: 10.1159/000360229 – volume: 26 start-page: 954 issue: 8 year: 2017 ident: 5549_CR25 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4233 – ident: 5549_CR55 – volume: 103 start-page: 1052 issue: 6 year: 2018 ident: 5549_CR36 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.865 – volume: 26 start-page: 2424 issue: 5 year: 2017 ident: 5549_CR38 publication-title: Stat Methods Med Res doi: 10.1177/0962280215598665 – year: 2007 ident: 5549_CR54 publication-title: Med Care doi: 10.1097/01.mlr.0000257193.10760.7f – volume: 73 start-page: 691 issue: 5 year: 2012 ident: 5549_CR6 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04167.x – ident: 5549_CR24 – volume: 109 start-page: 1172 issue: 5 year: 2013 ident: 5549_CR9 publication-title: Br J Cancer doi: 10.1038/bjc.2013.464 – volume: 52 start-page: 933 issue: 11 year: 2014 ident: 5549_CR51 publication-title: Int J Clin Pharmacol Ther doi: 10.5414/CP202172 – volume: 108 start-page: 1515 issue: 7 year: 2013 ident: 5549_CR11 publication-title: Br J Cancer doi: 10.1038/bjc.2013.116 – volume: 98 start-page: 1524 issue: 12 year: 2015 ident: 5549_CR28 publication-title: Patient Educ Couns doi: 10.1016/j.pec.2015.05.013 – volume: 28 start-page: 80 issue: 1 year: 2019 ident: 5549_CR34 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4647 – volume: 48 start-page: 284 issue: 2 year: 2014 ident: 5549_CR50 publication-title: Rev Saude Publica doi: 10.1590/S0034-8910.2014048004799 – volume-title: Group-based modeling of development year: 2005 ident: 5549_CR14 doi: 10.4159/9780674041318 – volume: 24 start-page: 1105 issue: 10 year: 2015 ident: 5549_CR18 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.3787 – volume: 3 start-page: e195 issue: 4 year: 2012 ident: 5549_CR45 publication-title: Health Outcomes doi: 10.1016/j.ehrm.2012.10.001 – volume: 32 start-page: 2318 issue: 22 year: 2014 ident: 5549_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.7367 – volume: 8 start-page: 521 issue: 3 year: 2014 ident: 5549_CR26 publication-title: J Cancer Surviv doi: 10.1007/s11764-014-0374-2 – volume: 156 start-page: e132 year: 2015 ident: 5549_CR33 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2015.07.363 – volume: 23 start-page: 882 issue: 4 year: 2012 ident: 5549_CR53 publication-title: Ann Oncol doi: 10.1093/annonc/mdr330 – volume: 28 start-page: 4120 issue: 27 year: 2010 ident: 5549_CR40 publication-title: J Clin Oncol doi: 10.1200/jco.2009.25.9655 – volume: 19 start-page: 105 issue: 2 year: 2013 ident: 5549_CR43 publication-title: J Oncol Pharm Pract doi: 10.1177/1078155212455939 – volume: 20 start-page: 632 issue: 6 year: 2014 ident: 5549_CR47 publication-title: Breast J doi: 10.1111/tbj.12328 – volume: 37 start-page: 423 issue: 5 year: 2019 ident: 5549_CR1 publication-title: J Clin Oncol doi: 10.1200/jco.18.01160 – volume: 3 start-page: 1 issue: 1 year: 2014 ident: 5549_CR41 publication-title: SpringerPlus doi: 10.1186/2193-1801-3-282 – volume: 42 start-page: 608 issue: 4 year: 2013 ident: 5549_CR39 publication-title: Sociol Methods Res doi: 10.1177/0049124113503141 – volume: 29 start-page: 374 issue: 3 year: 2001 ident: 5549_CR31 publication-title: Sociol Methods Res doi: 10.1177/0049124101029003005 – volume: 305 start-page: 1669 issue: 16 year: 2011 ident: 5549_CR37 publication-title: JAMA doi: 10.1001/jama.2011.506 – year: 2019 ident: 5549_CR19 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4751 – volume: 51 start-page: 789 issue: 9 year: 2013 ident: 5549_CR17 publication-title: Med Care doi: 10.1097/MLR.0b013e3182984c1f – volume: 138 start-page: 325 issue: 1 year: 2013 ident: 5549_CR4 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2422-4 – volume: 99 start-page: 1763 issue: 11 year: 2008 ident: 5549_CR12 publication-title: Br J Clin Pharmacol doi: 10.1038/sj.bjc.6604758 – start-page: 355 volume-title: Drug utilization research year: 2016 ident: 5549_CR8 doi: 10.1002/9781118949740.ch34 – volume: 134 start-page: 459 issue: 2 year: 2012 ident: 5549_CR5 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-2114-5 – volume: 122 start-page: 2010 issue: 10 year: 2015 ident: 5549_CR35 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2015.06.039 – volume-title: La vie deux ans après un diagnostic de cancer year: 2014 ident: 5549_CR21 – volume: 6 start-page: 109 year: 2010 ident: 5549_CR15 publication-title: Annu Rev Clin Psychol doi: 10.1146/annurev.clinpsy.121208.131413 – volume: 31 start-page: 328 issue: 6 year: 2015 ident: 5549_CR46 publication-title: Kaohsiung J Med Sci doi: 10.1016/j.kjms.2015.04.002 – volume: 27 start-page: 3445 issue: 21 year: 2009 ident: 5549_CR48 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.2419 – volume: 14 start-page: 397 year: 2014 ident: 5549_CR49 publication-title: BMC Cancer doi: 10.1186/1471-2407-14-397 |
| SSID | ssj0009709 |
| Score | 2.4413853 |
| Snippet | Purpose
Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET... Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET adherence is... Purpose Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET... PurposeDespite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET... Purpose: Despite the benefits of adjuvant endocrine therapy (AET) for reducing recurrence and mortality risks after hormone-sensitive breast cancer, AET... |
| SourceID | hal proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 777 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Analysis Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal - therapeutic use Breast cancer Breast Neoplasms Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer research Chemotherapy Chemotherapy, Adjuvant Cohort analysis Databases, Factual Endocrine therapy Epidemiology Female Follow-Up Studies Humans Life Sciences Medication Adherence Medication Adherence - psychology Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Metastases Metastasis Middle Aged Oncology Oncology, Experimental Patient compliance Prevention Prognosis Retrospective Studies Women Young Adult |
| SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELaglRAX3o9AgUECcYBUzstxuK1QywooJ1Yqp8h2bLqFZtGuF1F-GT-PGSfZZSkg9RbJE9uJx19m4plvGHtiCqVF3lRxJfMizpvMxLo0LjY2MVooUbhAYHrwXown-ZvD4rBPClsM0e7DkWRA6t-S3dCXicnd4QVdoeW4XaCDgttxe_T649u9Ndlu2YV2EKe3kFz0yTJ_72Xjg9TD8sUjioo8a3KeOS4NX6H9q2wyzL8LPvm8u_R61_z4g9rxvA94jV3pzVIYdXp0nV2w7Q126aA_eL_Jfo6aoy4xEPxcHYdf_ehjw8yBao6XaI57sG0zM5RMCF1S1ylMW7oEh4gKp7ilFhBKksPUL7Bt6ju1gFDwCAIXBNB_YWhnbXxivaJsp6kBTYHzHgwp6PwlKKCqvnMPgRoXKHL_E85iTQKMo1HgK32gF7fYZH_vw6tx3Bd9iA3Cg48L7QR3ZeZSUTSVS8uK7P_SINYgEidKoUPIS4dvTAubOJ7r3FqVWFuqzFRZkt1mWzhLe5eBNNag-5dqXqGY5DopJTdSZrlDFGuaiCXDytemZ0Snwhxf6jWXMy1JjUtShyWpv0fs-eqerx0fyH-lH5FC1V1O6wpM6pFIpKxSLmTEngUJghMc26g-KwKfgIi5NiR3NiQRBsxG81NU2tWciDV8PHqH0ohkJzXPUk4lqb4l2M2g1nUPV4sa7bZMlmUlecQer5ppBArBa-1sSTIiRXtU8DRid7rtsBoNeyfexCJiLwbVXnf-79dz73zi99nlNOwOipvaYVt-vrQP0CT0-mGPAL8AmKVYeQ priority: 102 providerName: Springer Nature |
| Title | Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases |
| URI | https://link.springer.com/article/10.1007/s10549-020-05549-x https://www.ncbi.nlm.nih.gov/pubmed/32086655 https://www.proquest.com/docview/2383877980 https://www.proquest.com/docview/2362071602 https://inserm.hal.science/inserm-03203214 |
| Volume | 180 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYJiFeEN9kjGEkEA8QYefDdnhB6dRSAasQolJ5ihzHYZ22dLQp2v4z_jzuHLdVNbGXJJIvtpPznc_23e8IeWVSXYqkysJMJWmYVLEJS2nq0FhuSqFFWjsA0-ORGI6Tz5N04jfcFt6tcqUTnaKuZgb3yN_D1BIrKTPFPl78DjFrFJ6u-hQaO2SPgyWCqRvkRG5Ad2Xn4oHY3kIx4YNmfOgcrIxCXDyxFJ8utyYmr553TtA78rrpee3Y1M1Gg3vkrjcjad7x_T65ZZsH5PaxPyh_SP7m1UkXyEfbuT51W_OwJqazmurqdAnmc0ttA1-NwX-0C8K6otMGH2kNGpBegQgsqEshTqftAsqmbcdG6hIUUYfdQHEflzazJjy3rcbopKmhJTq6t9TggJp_oJpiFt55Sx2ULUVP-1_Qiw1oL7SGjqo4oS4ekfGg_-NoGPokDaEBcW7DtKwFq2VcRyKtsjqSGdrr0oBuAM3JtYYFHJM1_PRSWF6zpEys1dxaqWOTxTx-THahl_YpocpYA8u1qGQZkClWcqmYUSpOatA6VRUQvuJQYTyCOSbSOCs22MvI1QK4WjiuFpcBebt-56LD77iR-gUyvuhiUNfCX-SCK5VFTKiAvHEUKP7QttE-igG-AIG0tigPtihBbM1W8WsYXOs-Icr3MP8K1KB5zgtMa48ppP5wqGY1_AqvXhbFRhgC8nJdjC2gy1xjZ0ukERHYj4JFAXnSDdt1a1A74hymAXm3Gsebyv__e_Zv7sszcidyAoV-TQdkt50v7XMw2dry0MklXNURPyR7-aDXG-H9088vfbj3-qNv36F0HOX_AJ2dRDQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2IQEviG8Cgx0SEw8Q4XzZDhJCFTB1rN3TJvUtJI7NOrF0tCms_xTP_HncOUmramJve4vki-34zue7-O53jL3SSV6IuEz9VMWJH5eR9gupra9NoAuRi8Q6ANPhoegfx19HyWiD_elyYSisstOJTlGXE03_yN_h0RIpKVPFP57_9KlqFN2udiU0GrE4MIvf6LLNPux_Rv7uhuHel6NPfb-tKuBrlL_aTworuJWRDUVSpjaUKRmYUqMw41YP8hw9Di5twHkhTGB5XMTG5IExMo90GgUR9rvJbsR0xYj7R47kCuRXNiElhCUuFBdtkk6bqoeemE_OGk_o6WLtIGyPg80Tisa8bOpeuqZ1p9_eXXanNVuh18jZPbZhqvvs5rC9mH_A_vbKkyZxEOppfuquAtAHh4mFvDydo7leg6lwlSnZEJqkrwWMK3oEixoXFri2M3Aly2Fcz7BtXDdiA64gEjisCKD_xlBNKv_M1DllQ401FBRYX4MmAZ6-hxyo6u-0BgedCxTZ_x1nsQIJxtEoMJYO8NlDdnwt7HvEtnCW5gkDpY1G9zAseIpkiheBVFwrFcUWtVxZeizoOJTpFjGdCnf8yFZYz8TVDLmaOa5mFx57s3znvMELuZJ6hxifNTmvS2WT9USgVBpyoTz22lGQusGxdd5mTeAXEHDXGuX2GiWqCb3WvIvCtZwToYr3ewOkRk13lvEo5FSy6leA3XTil7XqbJatNp_HXi6baQQK0avMZE40IkR7VfDQY48bsV2Ohr0TrmLisbedHK86___yPL16LjvsVv9oOMgG-4cHz9jt0G0uiqnaZlv1dG6eo7lYFy_cHgX27bqVwj-ljHpR |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELf2IU28IL7JGMxITDxANOfLcZAmVNiqjm3VhJi0t-A4Nuu0paNNYf3P-Bv4q7hznFbVxN72FslX282d7yO--x0hb1QiCx6XmZ-JOPHjMlJ-kSrjKx2ogkueGAtgetTnvZP4y2lyukT-trUwmFbZ6kSrqMuhwm_k22BaIpGmmWDbxqVFHO92P1799LGDFN60tu00pGuzUO5YuDFX5HGgp78hnBvv7O8C77fCsLv37XPPdx0HfAWyWftJYTgzaWRCnpSZCdMMnc9UgaCDGgikhGiEpSZgrOA6MCwuYq1loHUqI5VFQQTzLpPVFKw-BIKrn_b6x1_nEMBpk3CCSONcMO5KeFwhH8RpPoZyLMGn6wUz6YzF8hnmat50hG9c4lrb2H1A7junlnYaKXxIlnT1iKwduWv7x-RPpzxrygppPZLn9qIAInQ6NFSW5xNw5muqK-ABliLSpiRsSgcVPlID-phO4e2OqW1oTgf1GMYGdSNU1LZLohZJguJXZVoNK_9S1xJrpQaKFph2X1OF4j36QCXFnsCjmlpgXYp5_z9gF3MIYVgN02bRvI-fkJM7YeBTsgK71M8JFUorCB7DgmVAJlgRpIIpIaLYgA4sS48ELYdy5fDUsa3HRT5Hgkau5sDV3HI1v_bIu9lvrho0kVupN5HxeVMRO1NFeYcHQmQh48Ijby0FKiNYW0lXUwH_AGG9Fig3FihBiaiF4S0QrtmeEHO81zkEatCDlzmLQoYNrX4FME0rfrlTduN8fjQ98no2jCtgAl-lhxOk4SF4s5yFHnnWiO1sNZgdURcTj7xv5Xg--f9fz_rte9kka6Ag8sP9_sELci-0ZwsTrjbISj2a6JfgS9bFK3dIKfl-13rhH3_NhSw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+trajectories+of+adjuvant+endocrine+therapy+in+the+five+years+after+its+initiation+among+women+with+non-metastatic+breast+cancer%3A+a+cohort+study+using+administrative+databases&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=Lambert-C%C3%B4t%C3%A9%2C+Laurence&rft.au=Bouhnik%2C+Anne-D%C3%A9borah&rft.au=Bendiane%2C+Marc-Karim&rft.au=B%C3%A9renger%2C+Cyril&rft.date=2020-04-01&rft.pub=Springer+Verlag&rft.issn=0167-6806&rft.eissn=1573-7217&rft.volume=180&rft.issue=3&rft.spage=777&rft.epage=790&rft_id=info:doi/10.1007%2Fs10549-020-05549-x&rft_id=info%3Apmid%2F32086655&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai_HAL_inserm_03203214v1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon |